Children who miss diphtheria, tetanus toxoid, and acellular pertussis (DTaP) vaccine doses are at more likely to develop whooping cough, according to a study in JAMA Pediatrics.
Children who miss diphtheria, tetanus toxoid, and acellular pertussis (DTaP) vaccine doses are at more likely to develop whooping cough, according to a study in JAMA Pediatrics.
Jason Glanz, PhD, of Kaiser Permanente Colorado, and colleagues studied the correlation between undervaccination and pertussis in children 3 to 36 months old. They examined data from 8 managed care organizations in the Vaccine Safety Datalink between 2004 and 2010. For purposes of the study, undervaccination for the DTaP vaccine was defined as missing or delaying 1 or more of the first 4 doses by the recommended age.
They found that children who missed 3 doses of the DTaP vaccine were nearly 19 times more likely to develop pertussis than those who received the recommended number of doses. Children who missed 4 doses were 28 times more likely to develop whooping cough.
Last year, more than 41,000 cases of whooping cough were reported to the U.S. Centers for Disease Control and Prevention. Texas and California have reported whooping cough epidemics. Some medical experts attribute the increased incidence to parents who opt not to get their children the DTaP vaccine. Healthcare barriers and medical contraindication have also contributed to the trend.
In the study, 47% of the whooping cough cases belonged to children who were undervaccinated for DTaP. Nearly 30% of the undervaccinated children who developed pertussis are believed to have parents who “intentionally refused or delayed vaccine doses for personal, nonmedical reasons," the study report said.
Glanz and his colleagues believe 36% of identified pertussis cases identified in the study could have been prevented with on-time vaccination.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More